TScan Therapeutics, Inc.
TCRX
$1.27
-$0.11-7.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -70.15% | -86.62% | -44.71% | -25.65% | -14.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -70.15% | -86.62% | -44.71% | -25.65% | -14.47% |
| Cost of Revenue | 64.21% | 68.50% | -81.41% | -84.24% | -91.10% |
| Gross Profit | -160.47% | -111.17% | 91.05% | 101.04% | 117.86% |
| SG&A Expenses | 24.03% | 14.92% | 7.95% | 6.17% | 8.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.28% | 20.20% | 19.64% | 25.06% | 29.12% |
| Operating Income | -36.84% | -44.26% | -31.64% | -35.13% | -39.43% |
| Income Before Tax | -35.83% | -42.91% | -26.01% | -27.99% | -33.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.83% | -42.91% | -26.01% | -27.99% | -33.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.83% | -42.91% | -26.01% | -27.99% | -33.28% |
| EBIT | -36.84% | -44.26% | -31.64% | -35.13% | -39.43% |
| EBITDA | -40.42% | -48.37% | -34.75% | -38.42% | -43.08% |
| EPS Basic | -1.22% | -3.80% | 18.58% | 26.78% | 32.60% |
| Normalized Basic EPS | -0.27% | -2.98% | 18.58% | 26.78% | 32.60% |
| EPS Diluted | -1.22% | -3.80% | 18.58% | 26.78% | 32.60% |
| Normalized Diluted EPS | -0.27% | -2.98% | 18.58% | 26.78% | 32.60% |
| Average Basic Shares Outstanding | 53.36% | 26.15% | 40.94% | 64.31% | 97.80% |
| Average Diluted Shares Outstanding | 53.36% | 26.15% | 40.94% | 64.31% | 97.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |